SYNVAX, INC.

Company Information
Address SYNVAX, INC.
1770 N RESEARCH PKWY, STE 125
NORTH LOGAN, UT, 84341-0195


Information

DUNS:

# of Employees: N/A


Ownership Information

Hubzone Owned: N

Socially and Economically Disadvantaged: N

Woman Owned: N



Award Charts




Award Listing

  1. Development of Antifungals of Clinical Importance

    Amount: $162,637.00

    DESCRIPTION (provided by applicant): Fungal infections have increased dramatically in recent years to become important causes of mortality in hospitalized patients. The increase in life-threatening f ...

    SBIRPhase I2004Department of Health and Human Services
  2. DEVELOPMENT OF NOCICEPTIN-BASED ANALGESICS

    Amount: $0.00

    N/A

    SBIRPhase I2001Department of Health and Human Services
  3. DEVELOPMENT OF NOCICEPTIN-BASED ANALGESICS

    Amount: $473,591.00

    N/A

    SBIRPhase II2001Department of Health and Human Services
  4. DEVELOPMENT OF NOCICEPTIN BASED ANALGESICS

    Amount: $99,959.00

    Not Available SPRAY TRIODE electrostatic fuel atomizers are ideally suited for use in portable power systems. Spray droplet formation and dispersion being purely electrical in nature is achieved at l ...

    SBIRPhase I1999Department of Health and Human Services
  5. Development of Antivirals for Influenza

    Amount: $732,952.00

    Influenza viruses, a class of single-stranded RNA virus, continue to cause serious respiratory disethe world. Type A influenza virus causes pneumonia and deaths, especially in the elderly. Type B infi ...

    SBIRPhase II1998Department of Health and Human Services
  6. Development of Antivirals for Influenza

    Amount: $95,694.00

    Influenza viruses, a class of single-stranded RNA virus, continue to cause serious respiratory disethe world. Type A influenza virus causes pneumonia and deaths, especially in the elderly. Type B infi ...

    SBIRPhase I1995Department of Health and Human Services

Agency Micro-sites

US Flag An Official Website of the United States Government